TEM Tempus AI, Inc.
Tempus AI, Inc. operates as a healthcare technology company in the United States. It offers the Tempus platform, a closed-loop, full-stack, bi-directional integrations between a clinician's desktop and its laboratory diagnostic capabilities, analytics platform, and repository of multimodal data; and Hub, a clinical application for physicians and other healthcare providers for use in the diagnostics product line as an end-to-end application for healthcare providers for NGS tests. The company also provides Lens, a software application for life sciences and advanced precision research; diagnostics services, such as NGS diagnostics, PCR profiling, and other anatomic and molecular pathology tests; and large-panel solid tumor and hematologic testing through multiple assays, with its core clinical assay (xT and xR) offering large panel DNA, RNA full transcriptome, and incidental germline findings through normal blood or saliva analyses. In addition, it provides genetic tests focused on inherited conditions; an nP assay for pharmacogenomic testing for patients with psychiatric conditions, including depression, general anxiety disorder, bipolar disorder, and other relevant diagnoses; Insights, which licenses libraries of linked, de-identified clinical, molecular, and imaging data; Organoids, a tumor derived biological modeling. Further, the company offers Trials for clinical trial matching services; Next, an AI platform; Algos, an algorithm-based diagnostics application. It has Strategic Collaborations with AstraZeneca AB, Pathos AI, Inc., GlaxoSmithKline, Merck, and Recursion Pharmaceuticals, Inc. Additionally, it also has a strategic collaboration with Blood Cancer United to develop registry for pediatric acute myeloid leukemia. The company was formerly known as Tempus Labs, Inc. and changed its name to Tempus AI, Inc. in January 2023. Tempus AI, Inc. was incorporated in 2015 and is headquartered in Chicago, Illinois.…
Industry Peers
Health Information ServicesKey Statistics
About Tempus AI (NASDAQ: TEM)
›
Tempus AI (NASDAQ: TEM) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 3,800 employees.
The shares were at 59.61 USD on 19 November 2026, down 27.5% over 52 weeks. Its 52-week range is 40.77 USD to 89.09 USD: the price is 33.1% below the high and 46.2% above the low.
Its market capitalisation is 10.87B USD.
Tempus AI reports return on equity of -49.9%, an operating margin of -18.5% and revenue up 23.1% year over year.
Its debt exceeds its cash by 794.56M USD, a debt-to-equity ratio of 2.70. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 18 analysts cover the stock, with an average rating of Buy; their mean price target of 89.56 USD is 50.2% above the current price. The next earnings report is expected on 23 February 2027.